Unassociated Document
 

 
United States Securities And Exchange Commission
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): December 20, 2005
(December 14, 2005)
 
ISORAY, INC.
(Exact name of registrant as specified in its charter)
Minnesota
(State or other jurisdiction
of incorporation)
000-14247
(Commission
File Number)
41-1458152
(IRS Employer
Identification No.)

350 Hills Street, Suite 106, Richland, Washington 99354
(Address of principal executive offices) (Zip Code)

(509) 375-1202
(Registrant's telephone number)
 
 
ITEM 1.01 Entry into a Material Definitive Agreement
 
On December 14, 2005, IsoRay, Inc. (the "Registrant") entered into an Economic Development Agreement (the "Development Agreement") with the Pocatello Development Authority, an urban renewal agency formed under the laws of the State of Idaho ("PDA"). Pursuant to the Development Agreement, the PDA has provided the Registrant with $200,000 of funding (subject to repayment under certain conditions), to be used for costs associated with testing of production methods for Cesium-131 (a radioactive isotope used in the Registrant's brachytherapy seeds for the treatment of prostate and other cancers) at Idaho's Advanced Test Reactor.
 
ITEM 9.01 Exhibits
 
(c)  
Exhibits
 
 
10.25
Economic Development Agreement, dated December 14, 2005, by and between IsoRay, Inc. and the Pocatello Development Authority
 
SIGNATURES
 
In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
     
  IsoRay, Inc., a Minnesota corporation
 
 		  
 		  
 
Dated: December 20, 2005  By:   /s/ Roger E. Girard
 
Roger E. Girard, CEO